Vimta Labs to invest Rs. 50 crores to Biologics CDMO business foray
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
Delivers robust earnings performance, successfully navigating a dynamic environment
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Distribution agreement enables FUJIFILM India to offer Spectra Logic advanced tape libraries and software solutions to enterprise customers and channel partners
Bayer expects 2025 to be the most difficult year of its turnaround
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Phytonadione Injectable Emulsion possesses the same type and degree of activity as does naturally-occurring vitamin K
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
The transaction is expected to be completed by May 15, 2025 or such other date as may be mutually agreed
Subscribe To Our Newsletter & Stay Updated